GSK PLC

GSK PLC faces significant challenges after an FDA advisory panel votes against its Blenrep combination therapy, leading to a 5% drop in stock price and analyst downgrades.

GSK PLC faces challenges after a US FDA advisory panel voted against the approval of its Blenrep cancer treatment, leading to a decline in its stock price and a bearish outlook from analysts.

GSK PLC is under investigation by US Senator Maggie Hassan over its decision to discontinue a widely used asthma inhaler for children, allegedly to avoid a $367 million Medicaid rebate.

GSK PLC is navigating a mixed bag of developments, with promising advancements in oncology and antibiotics, but facing challenges in the market and regulatory environment.

GSK PLC has made significant strategic moves, including the acquisition of efimosfermin for up to $2 billion, to bolster its position in the healthcare sector and address critical health issues.